Ontology highlight
ABSTRACT:
SUBMITTER: Santini FC
PROVIDER: S-EPMC6089509 | biostudies-literature | 2017 Sep
REPOSITORIES: biostudies-literature
Santini Fernando C FC Rudin Charles M CM
Expert review of clinical pharmacology 20170727 9
<h4>Introduction</h4>The immune system can restrain or promote cancer development and growth. Antibodies targeting immune checkpoints have revolutionized cancer treatment. Among the best responses have been in non-small cell lung cancer (NSCLC) which is largely caused by chronic exposure to carcinogens; associated with high neoantigen creation and sensitization to immune recognition. Atezolizumab was the first approved antibody that targets the PD-1 ligand (PD-L1). Areas covered: This drug profi ...[more]